Provided by Tiger Trade Technology Pte. Ltd.

Annexon, Inc.

4.00
-0.0100-0.25%
Post-market: 4.000.00000.00%16:43 EDT
Volume:3.21M
Turnover:12.78M
Market Cap:760.00M
PE:-3.55
High:4.04
Open:3.99
Low:3.86
Close:4.01
52wk High:7.18
52wk Low:2.54
Shares:190.00M
Float Shares:164.00M
Volume Ratio:0.97
T/O Rate:1.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1271
EPS(LYR):-1.3445
ROE:-105.26%
ROA:-51.54%
PB:4.08
PE(LYR):-2.97

Loading ...

Annexon Falls on Bigger-than-Expected Quarterly Loss

Reuters
·
Aug 12

Annexon Shares Fall 6.4% Premarket After Wider-than-Expected Q2 Net Loss

THOMSON REUTERS
·
Aug 12

Annexon Q2 FY26 Net Loss Widens to $55.35 Million

Reuters
·
Aug 12

Annexon Q2 EPS $(0.28) Misses $(0.24) Estimate

Benzinga Earnings
·
Aug 12

Annexon Biosciences Q2 Net Loss Widens, Cash Runway Extended

Reuters
·
Aug 12

Earnings Flash (ANNX) Annexon Posts Q2 Loss $0.28 a Share, vs. FactSet Est of $0.23 Loss

MT Newswires Live
·
Aug 12

Annexon Biosciences Q2 Operating Expenses USD 57.227 Million

THOMSON REUTERS
·
Aug 12

Annexon Biosciences Q2 Basic EPS USD -0.28

THOMSON REUTERS
·
Aug 12

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

THOMSON REUTERS
·
Aug 12

Annexon Adds Month 24 Dual Primary Endpoint to Phase 3 Archer II Trial of Vonaprument in Geographic Atrophy

Reuters
·
Aug 12

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

THOMSON REUTERS
·
Aug 12

Annexon Names Mark Blumenkranz to Board as Muneer Satter Steps Down

Reuters
·
Aug 11

Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.d., M.m.s. to Its Board of Directors

THOMSON REUTERS
·
Aug 11

Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors

GlobeNewswire
·
Aug 11

Analysts Are Neutral on Top Healthcare Stocks: Annexon Biosciences (ANNX), RxSight (RXST)

TIPRANKS
·
Aug 08

Annexon Says Tanruprubart Shows Rapid Strength Gains in First 10 GBS Forward Study Patients

Reuters
·
Aug 06

Annexon Reports First U.S. and European Patient Cohort of Gbs Forward Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

THOMSON REUTERS
·
Aug 06

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

GlobeNewswire
·
Aug 06

Annexon Secures Credit Facility of up to $200 Million from Oxford Finance

Reuters
·
Jul 31

Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance

THOMSON REUTERS
·
Jul 31